Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | RORC | P51449 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BUB1 | O43683 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483240 | 0.82 | KDM4E (0.50) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL12422545 | 0.80 | F2RL3 (0.53) | F2RL3ALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL4483857 | 0.80 | F2RL3 (0.67) | F2RL3ALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL7745571 | 0.73 | F2RL3 (0.50) | F2RL3ALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL363569 | 0.73 | F2RL3 (1.00) | F2RL3ALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL29403731 | 0.73 | F2RL3 (1.00) | F2RL3ALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL19784752 | 0.71 | F2RL3 (0.79) | F2RL3ALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL9323633 | 0.70 | AKR1B1 (0.55) | TSHRMAPT | |
| SCHEMBL5564626 | 0.70 | PDE5A (0.72) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL4485942 | 0.69 | RORC (0.76) | F2RL3ALDH1A1KDM4EHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100516049-C | Antiangiogenic agent N2Synthesis of- (substituted arylmethyl) -3- (substituted phenyl) indazoles | YUNG SHIN PHARM IND CO LTD (CN) | 2009-07-22 | — | — | CN | disclosed |
| US-7514465-B2 | Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents | YUNG SHIN PHARM. IND. CO., LTD. (TW) | 2009-04-07 | — | — | US | disclosed |
| CN-1962640-A | Novel anti-angiogenic drug N2Synthesis of- (substituted arylmethyl) -3- (substituted phenyl) indazoles | YUNG SHIN PHARM IND CO LTD (CN) | 2007-05-16 | — | — | CN | disclosed |
| EP-1659115-A1 | Synthesis of substituted 2H-indazole derivatives as anti-angiogenic agents | Yung Shin Pharm. Ind. Co., Ltd. (TW) | 2006-05-24 | — | — | EP | disclosed |
| US-20060106032-A1 | Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents | YUNG SHIN PHARM. IND. CO., LTD. (TW) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106032-A1 | Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents | FLT4, FLT1, KDR | F2RL3 611/4885ALDH1A1 851/4885KDM4E 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.